Article

FDA reviewing ophthalmic laser

San Clemente, CA—Biolase Technology Inc. says the FDA is reviewing its 510(k) regulatory submission to obtain marketing clearance for the Oculase MD laser for use in ophthalmology and oculoplasty.

San Clemente, CA-Biolase Technology Inc. says the FDA is reviewing its 510(k) regulatory submission to obtain marketing clearance for the Oculase MD laser for use in ophthalmology and oculoplasty.

The company said it aims to market the laser for general tissue ablation, anterior capsulotomy (cataract removal), skin resurfacing, and the treatment of wrinkles around the eye and orbit. Biolase Technology designs, manufactures, and markets proprietary dental laser systems, including a system that uses water and a laser to cut hard and soft dental tissues.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
I. Paul Singh, MD, speaks about glaucoma treatment and successful ophthalmic / optometric comanagement at the 19th Annual Controversies in Modern Eye Care meeting
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
© 2025 MJH Life Sciences

All rights reserved.